Celgene Corporation (CELG) : Jennison Associates reduced its stake in Celgene Corporation by 0.06% during the most recent quarter end. The investment management company now holds a total of 14,097,772 shares of Celgene Corporation which is valued at $1,413,301,643 after selling 8,388 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on May 3, 2016.Celgene Corporation makes up approximately 1.50% of Jennison Associates’s portfolio.
Other Hedge Funds, Including , Montag Caldwell reduced its stake in CELG by selling 555,261 shares or 30.67% in the most recent quarter. The Hedge Fund company now holds 1,255,162 shares of CELG which is valued at $125,829,991. Celgene Corporation makes up approx 2.33% of Montag Caldwell’s portfolio. Diversified Trust Co sold out all of its stake in CELG during the most recent quarter. The investment firm sold 2,674 shares of CELG which is valued $268,069.Asset Dedication reduced its stake in CELG by selling 54 shares or 4.62% in the most recent quarter. The Hedge Fund company now holds 1,114 shares of CELG which is valued at $115,199. Celgene Corporation makes up approx 0.08% of Asset Dedication’s portfolio.Legacy Private Trust reduced its stake in CELG by selling 2,572 shares or 5.03% in the most recent quarter. The Hedge Fund company now holds 48,524 shares of CELG which is valued at $5,362,872. Celgene Corporation makes up approx 0.80% of Legacy Private Trust’s portfolio.Transamerica Financial Advisors reduced its stake in CELG by selling 698 shares or 15.28% in the most recent quarter. The Hedge Fund company now holds 3,871 shares of CELG which is valued at $427,823. Celgene Corporation makes up approx 0.04% of Transamerica Financial Advisors’s portfolio.
Celgene Corporation opened for trading at $102.8 and hit $103.48 on the upside on Tuesday, eventually ending the session at $103.25, with a gain of 0.82% or 0.84 points. The heightened volatility saw the trading volume jump to 29,17,398 shares. Company has a market cap of $79,978 M.
On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.